RE:RE:RE:RE:RE:RE:RE:Same old same old?I am pretty sure the team at Sirona has benefited greatly from their experience working with a well regarded industry and expert like Linda Pullan.
Logic should dictate that she agreed to work with them because the science in front of her was something that could be viable under a partnering scenario. I have confirmed some months ago that she will continue to remain on board to assist with future pipelines.
Logic also dictates that since Linda is on board and the most recent news release quoted some pretty bold statements about the future of the company in near future, that we would see a development before the summer months. If that logic holds with investors, then the number of weeks before the beginning of July where they could announce some big deals is narrowing down considerably.
And logic would also dictate that if Linda remains on board and an announcement about a Top10 deal is made, that this will immediately signal to the four partners in the pets diabetes pipeline discussion that the science does indeed have high commercial value and hence we may see a deal thereafter with yet another Top tier pharma in the pet therapy business.
And finally, if the Top10 does also have an anti-aging pipeline they wish to improve, or wants to enter that market, then Sirona's scientific platform around anti-aging could be the third successive target.
I say lets wait for miracle number 1 to happen before dreaming about miracles 2 & 3.